| Date | Title | Description |
| 27.07.2026 | Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma) | Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma)
Mon, Jul 27, 2026 07:01 CET Report this content
Copenhagen, 27 July 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURA... |
| 22.06.2026 | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million
Mon, Jun 22, 2026 23:11 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED ST... |
| 22.06.2026 | Curasight A/S announces its intention to carry out a directed issue of shares | Curasight A/S announces its intention to carry out a directed issue of shares
Mon, Jun 22, 2026 18:43 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG ... |
| 08.06.2026 | Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma) | Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma)
Mon, Jun 08, 2026 07:05 CET Report this content
Copenhagen, 8 June 2026 - Curasight A/S (“Curasight” or “the Co... |
| 28.05.2026 | Interim report Q1 2026 | Interim report Q1 2026
Thu, May 28, 2026 07:00 CET Report this content
Copenhagen, Denmark, 28 May 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platfor... |
| 26.04.2026 | Major Shareholding Notification - share transfer and ownership restructuring – related party transaction | Major Shareholding Notification - share transfer and ownership restructuring – related party transaction
Sun, Apr 26, 2026 21:41 CET Report this content
Copenhagen, 26 April 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS... |
| 25.03.2026 | Resolutions of the Annual General Meeting 2026 of Curasight A/S | Resolutions of the Annual General Meeting 2026 of Curasight A/S
Wed, Mar 25, 2026 17:14 CET Report this content
Copenhagen, Denmark, 25 March 2026 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its ... |
| 10.03.2026 | Notice of Annual General Meeting 2026 | Notice of Annual General Meeting 2026
Tue, Mar 10, 2026 18:26 CET Report this content
March 25, 2026
The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TIC... |
| 06.03.2026 | Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade | Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade
Fri, Mar 06, 2026 18:26 CET Report this content
Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) issued a convertible loan note to Fenja ... |
| 27.02.2026 | Curasight Accelerates Clinical Pipeline, Fortifies Financial Position | Curasight A/S achieved significant milestones in 2025. The company launched its Phase 1 uTREAT® glioblastoma trial, advancing its innovative radioligand therapy platform. uTRACE® also progressed in prostate cancer trials. Financial reports ... |
| 26.02.2026 | Annual Report 2025 | Annual Report 2025
Thu, Feb 26, 2026 08:05 CET Report this content
Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand therap... |
| 26.02.2026 | Year-end report Q4 2025 | Year-end report Q4 2025
Thu, Feb 26, 2026 08:00 CET Report this content
Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS), a clinical-stage radiopharmaceutical company pioneering a first-in-class uPAR-targeted radioligan... |
| 17.02.2026 | Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston | Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston
Tue, Feb 17, 2026 06:59 CET Report this content
COPENHAGEN, Denmark, February 17, 2026 - Curasight A/S (TICKER:CURAS) a clinical-stage radiopharmaceutical compa... |
| 09.02.2026 | Major Shareholding Notification | Major Shareholding Notification
Mon, Feb 09, 2026 17:16 CET Report this content
Copenhagen, 9 February 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that Pentwater C... |
| 12.01.2026 | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas
Mon, Jan 12, 2026 18:00 CET Report this content
Clear uptake of uTREAT® in aggressive brain ca... |
| 05.01.2026 | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
Mon, Jan 05, 2026 10:30 CET Report this content
Copenhagen, 5 January 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) a clinical-s... |
| 29.12.2025 | Resolutions of the Extraordinary General Meeting December 2025 | Resolutions of the Extraordinary General Meeting December 2025
Mon, Dec 29, 2025 10:31 CET Report this content
Copenhagen, 29 December 2025 – Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) today held its Extraordinary General ... |
| 29.12.2025 | Curasight A/S resolves to issue a convertible loan note | Curasight A/S resolves to issue a convertible loan note
Mon, Dec 29, 2025 13:18 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, N... |
| 18.12.2025 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer
Thu, Dec 18, 2025 17:19 CET Report this content
Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uT... |
| 14.12.2025 | Notice of Extraordinary General Meeting | Notice of Extraordinary General Meeting
Sun, Dec 14, 2025 17:34 CET Report this content
The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company”) to an Extraordinary General Meeting on
29 Decem... |
| 12.12.2025 | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility
Fri, Dec 12, 2025 22:37 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIR... |
| 12.12.2025 | Curasight A/S announces its intention to carry out a directed issue of shares and enter into a new loan facility | Curasight A/S announces its intention to carry out a directed issue of shares and enter into a new loan facility
Fri, Dec 12, 2025 18:38 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ... |
| 28.11.2025 | Curasight to present at HC Andersen Capital | Curasight to present at HC Andersen Capital
Fri, Nov 28, 2025 11:09 CET Report this content
Copenhagen, Denmark, 28 November 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich... |
| 27.11.2025 | Interim report Q3 2025 | Interim report Q3 2025
Thu, Nov 27, 2025 07:00 CET Report this content
Copenhagen, Denmark, 27 November 2025 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby publishes the interim report Q3 2025. The... |
| 26.11.2025 | Curasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | Curasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment
Wed, Nov 26, 2025 07:11 CET Report this content
Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT®
S... |
| 13.11.2025 | Curasight to present at Dansk Aktionærforening InvestorDagen | Curasight to present at Dansk Aktionærforening InvestorDagen
Thu, Nov 13, 2025 08:23 CET Report this content
Copenhagen, Denmark, 13 November 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announce... |
| 29.10.2025 | Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting | Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting
Wed, Oct 29, 2025 08:10 CET Report this content
Part 1 of the trial is completed
Part 2 recruitment well underway; completion ... |
| 01.10.2025 | Curasight announces broadening and extension of patent protection for uTRACE® | Curasight announces broadening and extension of patent protection for uTRACE®
Wed, Oct 01, 2025 07:00 CET Report this content
Issuance of new patent related to uTRACE® will broaden protection
Patent coverage has been extended by 751 days an... |
| 03.09.2025 | Transaction with shares in Curasight A/S made by managerial employee | Transaction with shares in Curasight A/S made by managerial employee
Wed, Sep 03, 2025 21:51 CET Report this content
Copenhagen, Denmark, 3 September 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby ... |
| 28.08.2025 | Half-year report Q2 2025 | Half-year report Q2 2025
Thu, Aug 28, 2025 07:00 CET Report this content
Copenhagen, Denmark, 28 August 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the half-year report 2025. The interim report is av... |
| 26.08.2025 | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT[®] in brain cancer patients | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT[®] in brain cancer patients
Tue, Aug 26, 2025 07:05 CET Report this content
Phase 1 study in aggressive brain cancer (Glioblastoma) is the firs... |
| 29.06.2025 | The Pulse of Innovation: Genetic Analysis and Curasight in the Spotlight | In the world of biotechnology, every announcement can feel like a heartbeat. Two companies, Genetic Analysis AS and Curasight A/S, recently made waves with their financial maneuvers. These moves reflect not just numbers, but the underlying ... |
| 23.06.2025 | Curasight A/S announces outcome of T03 warrant exercise | Curasight A/S announces outcome of T03 warrant exercise
Mon, Jun 23, 2025 17:35 CET Report this content
On 18 June 2024, the exercise period for warrants of series TO3, which were issued in connection with Curasight A/S (“Curasight” or the ... |
| 18.06.2025 | Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT[®] in brain cancer patients | Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT[®] in brain cancer patients
Wed, Jun 18, 2025 17:35 CET Report this content
Clinical Trial Application (CTA) submission marks progress in development of uTREAT® ... |
| 04.06.2025 | Genetic Analysis and Curasight: Navigating the Waters of Financial Offerings | In the world of finance, companies often seek new ways to raise capital. Two recent announcements from Genetic Analysis AS and Curasight A/S illustrate this trend. Both companies are making strategic moves to secure funding, but they are do... |
| 04.06.2025 | Curasight and YIT: Navigating the Financial Waters of Share Issues and Green Securities | In the world of finance, the tides can shift rapidly. Companies often find themselves navigating through complex waters, seeking opportunities to raise capital while adhering to regulatory frameworks. Two recent cases illustrate this dynami... |
| 03.06.2025 | The exercise period commences for warrants of series TO3 on 4 June 2025 | The exercise period commences for warrants of series TO3 on 4 June 2025
Tue, Jun 03, 2025 17:45 CET Report this content
Copenhagen, Denmark, 3 June 2025 - Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) hereby announces that th... |
| 02.06.2025 | Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue | Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue
Mon, Jun 02, 2025 08:15 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE ... |
| 28.05.2025 | Completed registration of rights issue | Completed registration of rights issue
Wed, May 28, 2025 17:25 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZ... |
| 28.05.2025 | Resolutions of the Annual General Meeting 2025 of Curasight A/S | Resolutions of the Annual General Meeting 2025 of Curasight A/S
Wed, May 28, 2025 14:26 CET Report this content
Copenhagen, Denmark, 28 May 2025 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its An... |
| 21.05.2025 | Curasight announces outcome in rights issue | Curasight announces outcome in rights issue
Wed, May 21, 2025 08:14 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, ... |
| 15.05.2025 | Subscription of new shares in the Right Issue 2025 exercised by Curasight management | Subscription of new shares in the Right Issue 2025 exercised by Curasight management
Thu, May 15, 2025 16:09 CET Report this content
Copenhagen, Denmark, 15 May 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CUR... |
| 13.05.2025 | Last day of the subscription period in Curasight’s rights issue of shares | Last day of the subscription period in Curasight’s rights issue of shares
Tue, May 13, 2025 08:46 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG... |
| 07.05.2025 | Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer | Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer
Wed, May 07, 2025 08:06 CET Report this content
Appointment of clinical CRO marks further step in progress in development of uTREAT as a potential new therapeutic... |
| 06.05.2025 | BioStock: Curasight’s rights issue subscription period has commenced | BioStock: Curasight’s rights issue subscription period has commenced
Tue, May 06, 2025 14:28 CET Report this content
Curasight is currently conducting a DKK 100 million rights issue, with the subscription period closing on May 16. Having se... |
| 03.05.2025 | Navigating the Waters of Corporate Finance: NORDEN and Curasight's Strategic Moves | In the ever-shifting landscape of corporate finance, companies often find themselves at a crossroads. Two recent announcements from NORDEN and Curasight illustrate this dynamic perfectly. Both firms are charting their courses through share ... |
| 02.05.2025 | THE SUBSCRIPTION PERIOD IN CURASIGHT’S RIGHTS ISSUE OF SHARES BEGINS TODAY | THE SUBSCRIPTION PERIOD IN CURASIGHT’S RIGHTS ISSUE OF SHARES BEGINS TODAY
Fri, May 02, 2025 07:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KON... |
| 30.04.2025 | Curasight to present at HC Andersen Capital | Curasight to present at HC Andersen Capital
Wed, Apr 30, 2025 12:17 CET Report this content
Copenhagen, Denmark, 30 April 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Kr... |
| 29.04.2025 | Curasight A/S publishes disclosure document regarding rights issue | Curasight A/S publishes disclosure document regarding rights issue
Tue, Apr 29, 2025 22:22 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN... |
| 25.04.2025 | Annual Report for the fiscal year 2024 | Annual Report for the fiscal year 2024
Fri, Apr 25, 2025 08:47 CET Report this content
Copenhagen, Denmark, 25 April 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal year ... |
| 25.04.2025 | Interim report Q1 2025 | Interim report Q1 2025
Fri, Apr 25, 2025 08:25 CET Report this content
Copenhagen, Denmark, 25 April 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report Q1 2025. The interim report is avai... |
| 24.04.2025 | CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE | CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE
Thu, Apr 24, 2025 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z... |
| 23.04.2025 | Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025 | Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025
Wed, Apr 23, 2025 11:38 CET Report this content
Copenhagen, Denmark, 23 April 2025 – today Curasight A/S ("Curasight" or the “Company" – TICKE... |
| 08.04.2025 | Notice of Extraordinary General Meeting of Curasight A/S | Notice of Extraordinary General Meeting of Curasight A/S
Tue, Apr 08, 2025 20:42 CET Report this content
The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) to an Extraord... |
| 04.04.2025 | Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million | Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million
Fri, Apr 04, 2025 17:14 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO TH... |
| 26.03.2025 | Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025 | Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025
Wed, Mar 26, 2025 07:00 CET Report this content
Copenhagen, Denmark, March 26, 2025 – Curasight A/S (“Curasight” or the “Company” – TICKER: CU... |
| 27.02.2025 | Year-end report Q4 2024 | Year-end report Q4 2024
Thu, Feb 27, 2025 07:00 CET Report this content
Business Highlights during the fourth quarter of 2024
Curasight designates brain cancer as initial indication for uTREAT®
Data from the Phase II uTRACE® trial in brain ... |
| 05.02.2025 | Curasight announces an updated financial calendar 2025 | Curasight announces an updated financial calendar 2025
Wed, Feb 05, 2025 09:24 CET Report this content
Copenhagen, Denmark, 5 February 2025 - Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) announces that the Company’s Annual G... |
| 12.12.2024 | Navigating the Waters of Capital Raises: A Look at ODI Pharma and Curasight | In the world of finance, capital raises are like tides. They ebb and flow, shaping the landscape of companies. Recently, two companies, ODI Pharma AB and Curasight A/S, made waves with their respective capital-raising efforts. Both firms fa... |
| 10.12.2024 | Participation in warrant exercise by Curasight management | Participation in warrant exercise by Curasight management
Tue, Dec 10, 2024 19:05 CET Report this content
Copenhagen, Denmark, 10 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces i... |
| 10.12.2024 | Curasight A/S announces outcome of warrant exercise | Curasight A/S announces outcome of warrant exercise
Tue, Dec 10, 2024 07:22 CET Report this content
Copenhagen, Denmark, 10 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces the out... |
| 02.12.2024 | The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024 | The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024
Mon, Dec 02, 2024 07:00 CET Report this content
The 3rd of December 2024 is the last day of trading in warrants of series TO2, which were issued in connectio... |
| 02.12.2024 | SEB maintain valuation range midpoint at DKK 54 per share | SEB maintain valuation range midpoint at DKK 54 per share
Mon, Dec 02, 2024 08:10 CET Report this content
Copenhagen, Denmark, 2 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces th... |
| 26.11.2024 | BioStock: Curasight CEO reflects on a Q3 with strong progress | BioStock: Curasight CEO reflects on a Q3 with strong progress
Tue, Nov 26, 2024 08:45 CET Report this content
Curasight recently released its Q3 report, reflecting on a period of good momentum. Publishing complete phase II results with uTRA... |
| 22.11.2024 | Curasight and Curium sign global radioisotope supply agreement for uTREAT[®] | Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]
Fri, Nov 22, 2024 08:25 CET Report this content
Agreement ensures supply of non-carrier-added Lutetium-177 for uTREAT® development and commercial supply including ... |
| 21.11.2024 | Curasight's Warrant Exercise: A New Chapter in Cancer Treatment | Curasight A/S is stepping into a pivotal moment. The exercise period for its warrants of series TO2 has begun. This marks a significant opportunity for investors and a potential boost for the company’s future. The exercise period runs from ... |
| 21.11.2024 | The exercise period for warrants of series TO2 commences today | The exercise period for warrants of series TO2 commences today
Thu, Nov 21, 2024 07:55 CET Report this content
Copenhagen, Denmark, 21 November 2024 - Today is the first day for the exercise of Curasight A/S’ ("Curasight" or "... |
| 21.11.2024 | Interim report Q3 2024 | Interim report Q3 2024
Thu, Nov 21, 2024 07:00 CET Report this content
Business Highlights during and after the third quarter of 2024
Curasight designates brain cancer as initial indication for uTREAT
Clinical Phase II trial of uPAR-PET in ... |
| 20.11.2024 | The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share | The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share
Wed, Nov 20, 2024 08:10 CET Report this content
Copenhagen, Denmark, 20 November 2024 - Curasight A/S ("Curasight" or "the Company" - ... |
| 14.11.2024 | Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference | Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference
Thu, Nov 14, 2024 07:00 CET Report this content
Copenhagen, Denmark, 14 November 2024 - Curasight A/S ("Curasight... |
| 13.11.2024 | Curasight announces international patent application for uTREAT® to broaden IP protection | Curasight announces international patent application for uTREAT® to broaden IP protection
Wed, Nov 13, 2024 07:05 CET Report this content
New patent application related to uTREAT will extend patent protection until 2043
Application adds sev... |
| 12.11.2024 | The BioStock Life Science Summit: A Nexus of Innovation and Investment | The BioStock Life Science Summit is a beacon for the Nordic life science community. Scheduled for November 20 and 21, 2024, in Lund, Sweden, this event promises to be a vibrant marketplace of ideas and opportunities. Picture a bustling hub ... |
| 11.11.2024 | Curasight will present at the BioStock Life Science Summit, November 21 | Curasight will present at the BioStock Life Science Summit, November 21
Mon, Nov 11, 2024 11:00 CET Report this content
The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CSO Andreas Kjaer wil... |
| 11.11.2024 | Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025 | Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025
Mon, Nov 11, 2024 07:00 CET Report this content
Brain cancer (high-grade glioma (HGG)) selected as first indication for uTREAT®
Addresses ... |
| 08.11.2024 | BioStock: Full phase II results of uPAR-PET in glioblastoma published | BioStock: Full phase II results of uPAR-PET in glioblastoma published
Fri, Nov 08, 2024 14:25 CET Report this content
Curasight has published the full data from an investigator-initiated phase II trial evaluating its uTRACE imaging technolo... |
| 08.11.2024 | Curasight to present at Dansk Aktionærforening InvestorDagen | Curasight to present at Dansk Aktionærforening InvestorDagen
Fri, Nov 08, 2024 10:42 CET Report this content
Copenhagen, Denmark, 8 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces... |
| 07.11.2024 | Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer | Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer
Thu, Nov 07, 2024 07:00 CET Report this content
Curasight’s radiopharmaceutical approach leverages the uPAR therano... |
| 11.10.2024 | Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3 | Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3
Fri, Oct 11, 2024 13:19 CET Report this content
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIR... |
| 03.10.2024 | Curasight A/S rights issue heavily oversubscribed | Curasight A/S rights issue heavily oversubscribed
Thu, Oct 03, 2024 08:41 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEA... |
| 14.09.2024 | Curasight and Brain+: Navigating the Waters of Rights Issues and Warrants | In the bustling world of biotech, companies often seek new avenues for funding. Two Danish firms, Curasight A/S and Brain+ A/S, recently made headlines with their respective rights issues and warrant exercises. These financial maneuvers are... |
| 12.09.2024 | Curasight A/S publishes prospectus due to upcoming rights issue | Curasight A/S publishes prospectus due to upcoming rights issue
Thu, Sep 12, 2024 12:22 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, C... |
| 10.09.2024 | BioStock: Curasight carries out the first step of capitalization | BioStock: Curasight carries out the first step of capitalization
Tue, Sep 10, 2024 08:15 CET Report this content
In late June, Curasight announced a capital raise package of up to DKK 120 million to finance the ongoing development of its th... |
| 05.09.2024 | DexTech and Curasight: Navigating the Waters of Medical Innovation and Financing | In the ever-evolving landscape of medical technology, two companies stand out: DexTech Medical AB and Curasight A/S. Both are charting their courses through clinical trials and financial maneuvers, aiming to bring innovative treatments to m... |
| 04.09.2024 | The Board of Directors resolves on a directed issue of units and preferential rights issue of units | The Board of Directors resolves on a directed issue of units and preferential rights issue of units
Wed, Sep 04, 2024 09:25 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED ST... |
| 22.08.2024 | Interim report Q2 2024 | Interim report Q2 2024
Thu, Aug 22, 2024 07:00 CET Report this content
Business Highlights during the second quarter 2024
Strengthened financial base with funding of DKK 27.8 million and potential of up to DKK 120 million in total.
Clinical... |
| 30.07.2024 | Curasight issues warrants as part of long-term incentive program | Curasight issues warrants as part of long-term incentive program
Tue, Jul 30, 2024 10:39 CET Report this content
Copenhagen, Denmark, 30 July 2024 - Curasight A / S ("Curasight" or the “Company"- TICKER: CURAS) announces toda... |
| 02.07.2024 | Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024 | Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024
Tue, Jul 02, 2024 14:11 CET Report this content
Copenhagen, Denmark, 2 July 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: C... |
| 01.07.2024 | Directed issues registered at the Danish Business Authority | Directed issues registered at the Danish Business Authority
Mon, Jul 01, 2024 11:53 CET Report this content
Copenhagen, Denmark, 01 July 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that... |
| 22.06.2024 | Curasight to present at HC Andersen Capital | Curasight to present at HC Andersen Capital
Sat, Jun 22, 2024 11:22 CET Report this content
Copenhagen, Denmark, 22 June 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Kra... |
| 17.06.2024 | Notice of Extraordinary General Meeting | Notice of Extraordinary General Meeting
Mon, Jun 17, 2024 16:05 CET Report this content
The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company”) to an Extraordinary General Meeting on
Tuesday ... |
| 14.06.2024 | Curasight A/S resolves on directed issues and a loan facility | Curasight A/S resolves on directed issues and a loan facility
Fri, Jun 14, 2024 17:22 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CAN... |
| 12.06.2024 | Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer | Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer
Wed, Jun 12, 2024 07:11 CET Report this content
Recruitment of first patient triggers second milestone payment of USD 500.000 to Curasight un... |
| 23.05.2024 | Interim report Q1 2024 | Interim report Q1 2024
Thu, May 23, 2024 07:00 CET Report this content
Business Highlights during the first quarter 2024
Announcing the achievement of the first milestone under the agreement with Curium Inc. to develop uTRACE® for improving... |
| 16.04.2024 | Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients | Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients
Tue, Apr 16, 2024 20:39 CET Report this content
Dosing of first patient expected 2Q 2024
CTA approval marks progre... |
| 12.04.2024 | Curasight announces change in the Board of Directors | Curasight announces change in the Board of Directors
Fri, Apr 12, 2024 11:58 CET Report this content
Copenhagen, April 12, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the chairperson of the Board of Di... |
| 21.03.2024 | Resolutions of the Annual General Meeting 2024 of Curasight A/S | Resolutions of the Annual General Meeting 2024 of Curasight A/S
Thu, Mar 21, 2024 12:30 CET Report this content
Copenhagen, Denmark, 21 March 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its ... |
| 11.03.2024 | Curasight not to proceed with rights issue; evaluating alternative financing opportunities | Curasight not to proceed with rights issue; evaluating alternative financing opportunities
Mon, Mar 11, 2024 21:53 CET Report this content
Copenhagen, Denmark, 11 March 2024 – Curasight A/S ("Curasight" or the “Company" – TIC... |
| 06.03.2024 | Notice of Annual General Meeting 2024 | Notice of Annual General Meeting 2024
Wed, Mar 06, 2024 11:26 CET Report this content
The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) on
... |
| 23.02.2024 | The subscription period in Curasight’s rights issue begins today | The subscription period in Curasight’s rights issue begins today
Fri, Feb 23, 2024 08:35 CET Report this content
Copenhagen, Denmark, 23 February 2024 - Today is the first day of the subscription period in Curasight A/S’s ("Curasight&q... |
| 22.02.2024 | Annual Report for the fiscal year 2023 | Annual Report for the fiscal year 2023
Thu, Feb 22, 2024 08:46 CET Report this content
Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal ye... |
